Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bedlack, R. S.
Right arrow Articles by Sanders, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bedlack, R. S.
Right arrow Articles by Sanders, D. B.
Related Collections
Right arrow Myasthenia
Right arrow Clinical trials Methodology/study design
NEUROLOGY 2005;64:1968-1970
© 2005 American Academy of Neurology
Brief Communications

Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity

R. S. Bedlack, MD, PhD, D. L. Simel, MD, H. Bosworth, PhD, G. Samsa, PhD, B. Tucker-Lipscomb, RN, MSN and D. B. Sanders, MD

From Duke University Medical Center and Durham VAMC, Durham, NC.

We prospectively tested the quantitative myasthenia gravis score (QMG) for responsiveness and longitudinal construct validity in 53 patients with myasthenia gravis. Index of responsiveness was high. Longitudinal construct validity was confirmed by the correlation between changes in QMG and manual muscle testing and by a difference in QMG changes across patients that were clinically unchanged, improved, or worse between two visits. Our results support QMG use for assessing clinical change in trials.

Sponsored by a grant from the Myasthenia Gravis Foundation of America.

Received November 29, 2004. Accepted in final form February 16, 2005.

Address correspondence and requests reprints to Dr. Richard S. Bedlack, Duke University Medical Center, Box 3333, Durham, NC 27705; e-mail: bedla001{at}mc.duke.edu




This article has been cited by other articles:


Home page
 NeurologyHome page
M. J. Bhanushali, J. Wuu, and M. Benatar
Treatment of ocular symptoms in myasthenia gravis
Neurology, October 21, 2008; 71(17): 1335 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
H. J. Kaminski
Restoring balance at the neuromuscular junction
Neurology, August 14, 2007; 69(7): 629 - 630.
[Full Text] [PDF]

Home page
 NeurologyHome page
Z. Argov, D. McKee, S. Agus, S. Brawer, N. Shlomowitz, O. B. Yoseph, H. Soreq, and J. D. Sussman
TREATMENT OF HUMAN MYASTHENIA GRAVIS WITH ORAL ANTISENSE SUPPRESSION OF ACETYLCHOLINESTERASE
Neurology, August 14, 2007; 69(7): 699 - 700.
[Full Text] [PDF]

Home page
 NeurologyHome page
L. Zinman, E. Ng, and V. Bril
IV immunoglobulin in patients with myasthenia gravis: A randomized controlled trial
Neurology, March 13, 2007; 68(11): 837 - 841.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.